Give our best to Chad, please.This concludes the Q&A for today. I'd say it ranks in our top two to three priorities, and I would also say that our optimism level is very high that we're going to be able to get the type of partnership that we want. While these numbers represent the cumulative cases, it's also important to recognize that there are currently nearly 2.4 million active cases here in the U.S. As of May 7, less than 80,000 COVID-19-related deaths had occurred in the U.S.And based on the seven-day rolling average as of that date, patient deaths were occurring at a rate of approximately 1,900 per day.

For the three months ended June 30, 2020, we recognized $84,000 in revenues, compared to $4.3 million for the three months ended June 30, 2019.$4.2 million of the revenues in the prior period were generated from our collaboration with Healios related to manufacturing services performed. As of that date, there were approximately 1.3 million confirmed cases of COVID-19 that has occurred here in the U.S.And as of today, there have been approximately 5.2 million confirmed cases, representing an increase of 3.9 million new cases in just three months. But if you look at the delta in terms of hospitalization and some of the other things that, frankly, they didn't talk about, it appears that the effects of that are not nearly as much as you would want at the end of the day in terms of being able to really help these patients on a path to speedy recovery and a higher probability of recovery and getting them out of the hospital and back on their way with hopefully full -- the full ability to actually regain their quality of life and functional independence. So we're all trying to get to a better place of stability as soon as we all can, but the reality of it is that we have to do the right things while we're trying to get to that point. And so I think some things are -- actually kind of ticked up while other things will tend to subside over time. As Jesse mentioned, I'm Karen Hunady, director of corporate communications and investor relations for Athersys.

I mean, the reality of it is that we're going at a very measured pace while we try to resolve things.

A single focal point is -- may not work.And in fact, our belief is that it won't work, and that is because a lot of emerging clinical data from people who have looked at what is happening in COVID-19-induced patients have correctly ascertained.

And my understanding is that that company is in discussions with BARDA for funding.It's unclear. By Peter Winter. The first is from the Department of Defense. Or are you guys on the hook for any costs there?Yeah, great question. We understand why people are focused on that and why people want to make as much progress on diagnostics, vaccines, and some of the antiviral therapies over the course of the next several months.

Can you just cover what the advantages are and what the issues might be into the future, dealing with ARDS, whether it's from COVID or whatever COVID becomes and then everything else that might take place? Personal Finance But given who we're in negotiations and discussions with, given the types of discussions that we've been having with people, our belief is that this is a very achievable goal, and we think we're in a really good position where we're at right now.Your next question comes from David Hoang with SMBC Nikko. But one of the things that we've always been committed to is thinking through how things should be done.So yes, we want to do things quickly and efficiently, but the reality of it is that we want to make sure that things are done properly.

However, we are encouraged that public health officials and school boards are taking the issue seriously and are implementing a range of protective measures, including offering online educational options for the fall term and likely beyond. I just have one quick follow-up that you had started down the path of specific to ARDS and the agnostic nature of MultiStem. I'm not saying -- I'm not trying to find the silver lining in the storm clouds. Thank you. Returns as of 08/15/2020. So the FDA has already signed off on the study design. I'm not going to go into detail on it today, but I think one of the things that appears to be resonating with people and that BARDA leadership correctly recognized early on was that, look, great if we find a magic bullet that focuses on one thing, some single cytokine or whatever it might be. As we always say, we're fully committed to advancing our programs and achieving our goals, and we look forward to making additional announcements and providing updates as we move forward.